These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32206355)

  • 1. Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience.
    Herrera-Escandón Á; Castaño-Cifuentes O; Plata-Mosquera CA
    Case Rep Cardiol; 2020; 2020():6927423. PubMed ID: 32206355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
    Crespo-Leiro MG; López-Vilella R; López Granados A; Mirabet-Pérez S; Díez-López C; Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Rangel-Sousa D; Blasco-Peiró T; de la Fuente-Galán L; Díaz-Molina B; Zatarain-Nicolás E; Carrasco Ávalos F; Almenar-Bonet L
    Clin Transplant; 2019 Dec; 33(12):e13748. PubMed ID: 31670852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy.
    Yasaka M; Yokota H; Suzuki M; Yamane T; Ono Y
    Cardiol Ther; 2020 Jun; 9(1):189-199. PubMed ID: 32394292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
    Fagundes V; Mesquita M
    Eur J Case Rep Intern Med; 2019; 6(12):001311. PubMed ID: 31893202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience with idarucizumab as a reverse agent of dabigatran].
    Bottaro FJ; Margan MM; Duboscq C; Ceresetto JM
    Medicina (B Aires); 2020; 80(4):405-410. PubMed ID: 32841148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.
    Izaguirre Ávila R; Bahena López JE; Cortina de la Rosa E; Hernández Márquez MÁ
    Eur Heart J Case Rep; 2019 Jun; 3(2):. PubMed ID: 31449648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of oral anticoagulants in older patients.
    Sebastian JL; Tresch DD
    Drugs Aging; 2000 Jun; 16(6):409-35. PubMed ID: 10939307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab in High-risk Thoracic Surgery.
    López-Vilella R; Sanz-Sánchez J; Sánchez-Lázaro I; Marques-Sule E; Rueda-Soriano J; Almenar-Bonet L
    Int J Organ Transplant Med; 2018; 9(2):97-100. PubMed ID: 30834094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study.
    Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Ochiai K; Nakayama D
    Cardiol Ther; 2020 Jun; 9(1):167-188. PubMed ID: 32152956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.